dete: 04/06/2007

PTO/SB/08B (09-06) Approved for use through 03/31/2070, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid Other Control number.

Complete if Known Application Number 10/570,737 INFORMATION DISCLOSURE Filing Date September 8, 2004 STATEMENT BY APPLICANT First Named Inventor Raphael Mechoulam Art Unit N/A (Use as many sheets as necessary) Examiner Name N/A Attorney Docket Number Sheet of 4 0-06-058/16434/US/03

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	١	BISOGNO, TIZIANA et al., British Journal of Pharmacology, 134 (4):845-852 (2001) XP002319199	
	2	CASU, M. A. et al. (2003) Eur. J. Pharmacol. 459(1): 97-105	
	3	CHESHER, G. B. et al. (1973) Br. J. Pharmacol. 49(4): 588-94	
	4	COLOMBO, G. et al. (1998) Eur. J. Pharmacol. 344(1): 67-9	
,	5	FRIDE, E. (1995) Brain Res. 697, 83	
	će	FRIDE, E. (2002) Endocannabinoids in the central nervous system - an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids	
	7	ERIDE, E. and C. SANLIDO-PENA (2002) Cannabinoids and endocannabinoids: behavioral and developmental aspects. In: The Biology of Marijuana, ed. E. Onaivi, Harwood Academic	
		Publishers, Reading	
	8	FRIDE, E. and R. MECHOULAM (1993) Eur. J. Pharmacol. 231, 313	
	9	GALIEGUE, S. et al. (1995) Eur. J. Biochem. 232(1): 54-61	

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to application. It is placed in the property of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 04/06/2007

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	er the Paperwork Red	uction Ac	t of 1995, no persons ar	are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitut	e for form 1449/P10			Application Number	10/570,737		
			CLOSURE	Filing Date	September 8, 2004		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Raphael Mechoulam		
	(Use as many she	ato on m	occessed.	Art Unit	N/A		
	(Use as many silv	015 05 II	cossary)	Examiner Name	N/A		
Sheet	2	of	4	Attorney Docket Number	0-06-058/16434/US/03		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	10	GARDNER, A.L. et al. (1988) Trends Pharmacol. Sci. Suppl.: 40-3	
	11	GRIFFIN, G. et al. (1997) Eur. J. Pharmacol. 339, 53	
	12	GURWITZ, D. et al. (1994) Eur. J. Pharmacol. 267, 21	
	13	HAEFELY, W. et al. (1990) Trends Pharmacol. Sci. 11(11): 452-6	
,	14	HANUS, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 14228	
	15	HERKENHAM, M. (1995) Cannabinoid receptors, London, Academic Press: 145-166	
	16	IZZO, A. et al. (2000) Br. J. Pharmacol. 129(8): 1627-32	
	17	IZZO, A.A. et al. (2001) Br. J. Pharmacol. 132, 1411	
	18	JOHNSON, M.R. and MELVIN, L.S. (1986) The discovery of non-classical cannabinoids analgetics. In: Cannabinoids as therapeutic agents. Ed. R.	
	19	Mechaulam, CK5 Press FL, 18 121-195 LANDI, M. et al. (2002) Eur. J. Pharmacol. 450, 77	

Examiner	/Brian Davis/	Date Considered	03/24/2010
Signature	75.14.1.54.16		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consources. Include copy of mis form with next communication to applicant. It is place a check mark here if English language Translation is associated. Applicant's into place a check mark here if English language Translation is associated. This collection of information is required by 37°C replicant in the place of the communication of the com Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

$\overline{}$	er the Paperwork Red e for form 1449/PTO	luction Ac	t of 1995, no persons a	are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute	9101101111114497-10			Application Number	10/570,737	
INFO	RMATION	DIS	CLOSURE	Filing Date	September 8, 2004	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Raphael Mechoulam	
	(Use as many she	ote se s	noncond.	Art Unit	N/A	
	(Use as many and	7013 G3 171	ocossery)	Examiner Name	N/A	
Sheet	3	of	4	Attorney Docket Number	0-06-058/16434/US/03	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	20	MALFAIT, A.M. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 9561			
	21	MARTIN, B. R. et al. (1991) Pharmacol. Biochem. Behav. 40(3): 471-8			
	22	MECHOULAM, R. et al. (1998) Prog. Med. Chem. 35, 199			
		MEGHOULAM, D. CRC-Press Fl., pp. 121-145			
,	23	PARKER, L.A. et al. (2002) Neuroreport 13, 567			
	24	PERTWEE, R.G. (1997) Pharmacol. Ther. 74, 129			
-	25	PERTWEE, R.G. (2001) Gut 48(6): 859-67			
	26	PINTO, L. (2002) Prostaglandins Leukot Essent Fatty Acids 66, 333			
	27	ROBSON, P. (2001) Br. J. Psychiatry 178, 107			
	28	TJOLSEN, A. and HOLE (1997) The Pharmacology of Pain, Springer, Heidelberg, pp.1-20]			

Examiner Signature	/Brian Davis/	Date Considered	03/24/2010
Signature		Constacted	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered, include copy of this form with next communication to applicant.

1 Applicants using student designation under (options). Applicant is to place a check mark here if English language Translation is unlessed.

This collection of information is required by 37 CPR 158. The information is placed as the place of the information is placed by the USPTO Translation of the information is placed by the USPTO applicant is being a placed by the USPTO applicant is estimated to take 2 hours to complete, including alternative placed by the USPTO. There will vary depending upon the included case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burder, should be sent to the Chief Information Officer. Selection 158 and 158 applicants are considered applicants and the Chief Information Officer. Selection 158 and 158 applicants are considered applicants and the Chief Information Officer. Selection 158 and 158 applicants are complete that the complete placed applicants are considered applicants and the complete placed applicants are considered applicants. The complete placed applicants are considered applicants and the complete placed applicants are considered applicants. The complete placed applicants are considered applicants and the complete placed applicants are considered applicants. The complete placed applicants are considered applicants and the complete placed applicants are considered applicants. The complete placed applicants are considered applicants and the complete placed applicants are considered applicants. The complete placed applicants are considered applicants are considered applicants and the complete placed applicants are considered as a complete placed applicants are c Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 04/06/2007

PTO/SB/08B (09-06) Approved for use through 03/31/2007, OMB 0651-0031

Und	der the Paperwork Red	uction A	t of 1995, no persons er		of information unless it contains a valid OMB control number.		
$\overline{}$	e for form 1449/PTO			Complete if Known			
Cubband	10 10 10 11 14 0 1 TO			Application Number	10/570,737		
INFO	DRMATION	DIS	CLOSURE	Filing Date	September 8, 2004		
STA	TEMENT E	Y A	PPLICANT	First Named Inventor	Raphael Mechoulam		
	(Use as many she	-4a aa -		Art Unit	N/A		
	(Use as many site	eis as n	ocessary)	Examiner Name	N/A		
Sheet	4	of	4	Attorney Docket Number	0-06-058/16434/US/03		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	29	Young, J. M. et al. (1984) J. Invest. Dermatol. 82, 367-71	
*			

Examiner	/Brian Davis/	Date	03/24/2010
Signature	/Dilaii Davis/	Considered	03/24/2010

EVEXAMINEF. Initial if reference considered, whether or not clasion is in conformance with MPEP 600. Draw time through clasion if not in conformance and not considered. Include copy in this form with next communication to applicate.

Projection:

In proj Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.